{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"275"},{"groupId":"OG002","value":"178"},{"groupId":"OG003","value":"98"},{"groupId":"OG004","value":"95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2261"},{"groupId":"OG001","value":"1878"},{"groupId":"OG002","value":"1455"},{"groupId":"OG003","value":"912"},{"groupId":"OG004","value":"500"}],"units":"Participants"}],"description":"An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Treatment discontinuation includes temporary and permanent discontinuation, drug modification, and second primary malignancies.","groups":[{"description":"The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG000","title":"1st Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG001","title":"2nd Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG002","title":"3rd Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG003","title":"4th Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in \\>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG004","title":">4th Line of Therapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received Takeda products and signed informed consent form were included in the analysis. As pre-specified in SAP, data for treatment-emergent adverse events was planned to be collected and reported for Takeda products only. Participants were counted more than once in each line of therapy towards the total. The data is reported as per the known line of therapies.","reportingStatus":"POSTED","timeFrame":"Baseline up to 5 years","title":"Number of Participants With Atleast One Treatment-emergent Adverse Events Leading to Treatment Discontinuation","type":"SECONDARY","unitOfMeasure":"Participants"}